Gentris Corporation Expands GentriSure Line of Human Genomic DNA Reference Controls
Controls for CYP2C9, VKORC1 and CYP2C19 genes eliminate informed consent and consistency issues for labs using leftover specimens or synthetic materials. - November 16, 2006
Gentris Corporation Announces New Addition to Scientific Advisory Board
Dr. Andrea Gaedigk of Children’s Mercy Hospital & Clinics joins advisory board of leading scientists. - November 09, 2006
Gentris Corporation Announces FDA 510(k) Submission for GentriSure™ Human Genomic DNA Reference Controls for CYP2D6 Gene
Submission represents significant milestone and growth potential for Gentris Diagnostics Division as FDA considers the relabeling of a breast cancer drug metabolized by CYP2D6. - October 27, 2006
Gentris Promotes Karen Nield to VP, Finance and Human Resources
Gentris Corporation (Gentris), a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, today announced the promotion of Karen Nield to VP, Finance and Human Resources. Prior to this promotion Nield held the position of Executive Director, Finance. - September 15, 2006
Gentris Partners with FALCO Biosystems
Companies establish Japan’s first GLP-compliant pharmacogenomics laboratory. - August 22, 2006
LGC and Gentris Corporation Announce Licensing Agreement
Gentris obtains rights from LGC to make, use and sell diagnostic products and services which include testing for the CYP2D6*4 polymorphism. - June 08, 2006
Gentris Announces UGT1A1 Sub-Licensing Agreement
Gentris obtains rights from Mayo Foundation for Medical Education and Research to provide genetic testing services for mutations associated with adverse reactions to irinotecan. - April 26, 2006
Gentris Corporation Introduces Human Genomic DNA Reference Controls for CYP2D6 Gene
Gentris Corporation, a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, today announced the availability of Human Genomic DNA Reference Controls for the Cytochrome P450 2D6 gene (CYP2D6). - April 13, 2006
Gentris Announces Promotion and Strategic New Hire
Scott Clark promoted to Vice President of Research and Development; Heath Knight joins as Vice President of Business Development - December 15, 2005
Gentris Joins Personalized Medicine Coalition
Educational and advocacy group to promote the advancement and understanding of personalized medicine. - December 05, 2005